AVITAR INC (OTCMKTS:AVTI) had a decrease of 0.15% in short interest. AVTI’s SI was 67,800 shares in May as released by FINRA. Its down 0.15% from 67,900 shares previously. With 200,300 avg volume, 0 days are for AVITAR INC (OTCMKTS:AVTI)’s short sellers to cover AVTI’s short positions. The stock decreased 25.00% or $0.0001 during the last trading session, reaching $0.0003. About 9.21M shares traded or 810.41% up from the average. Avitar, Inc. (OTCMKTS:AVTI) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.
Avitar, Inc. is a holding company which through its subsidiaries designs, develops, makes, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. The company has market cap of $41,455. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine such as crack; marijuana; and methamphetamines, including meth and ecstasy. It currently has negative earnings. The firm also provides foam disposable products including medical-grade hydrophilic polyurethane foam disposables such as wound dressings comprising Hydrasorb, a wound dressing product for exudating wounds; and various custom foam products comprising a sinus dressing and a device used by astronauts for relieving ear pressure while in a pressurized space suit.
